PRKDC and cancer: Notably, same salinomycin plus DNA-PKcs inhibitor treatment failed to induce significant cytotoxicity to the non-cancerous OB-6 osteoblastic cells, suggesting cancer cell specific response by the co-treatment (Figure 1E).